Endless Ark

Endless Ark (无尽方舟 / EonArk) is a Shenzhen-based AI longevity biotech startup founded in 2026 by Oxford-educated CEO Simiao Zhao and CTO Jingkun Zeng, a former UC Berkeley postdoc who trained under Nobel laureate Jennifer Doudna . The company builds a "Longevity Foundation Model" that learns cross-species, cross-organ single-cell and multi-omics data to identify anti-aging targets and compress the search space for multi-gene therapeutic combinations from millennia of wet-lab work down to hundreds of testable candidates .

Its dual-track strategy starts with pet therapeutics as a faster path to proof-of-concept and data accumulation, while preserving human drug conversion options. Lead programs include ARK-001 for canine age-related fibrosis, metabolic and inflammatory phenotypes, and ARK-002 on a classic aging pathway already protected by a Chinese invention patent . The company has assembled AI, drug development and precision health divisions, with a core team that includes six Oxford PhDs and multiple Nature/Science publications .

Endless Ark raised two rounds within a month in mid-2026 — a seed round led by Monolith with Unity Ventures, Boyu Capital and Guokr following, and a seed+ round led by Unity Ventures with Monolith, Boyu Capital and Starlink Capital joining — totaling nearly RMB 100 million at a valuation of several hundred million RMB .